News | November 09, 2025
SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Glenmark will begin distribution in November 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Panacea Biotec receives acceptance from CMSS for supply of bOPV
The inspection was carried out between May 26, 2025 and May 31, 2025
Alembic receives EIR from USFDA for facility at Panelav
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Subscribe To Our Newsletter & Stay Updated
